Eli Lilly and Company (LLY)
Eli Lilly (LLY) Earnings Expected to Grow: Should You Buy?
Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Eli Lilly (LLY) Rises Higher Than Market: Key Facts
Eli Lilly (LLY) closed the most recent trading day at $1, moving +2.09% from the previous trading session.
This Catalyst Makes Eli Lilly a Top Growth Stock in 2026
Eli Lilly (NYSE:LLY | LLY Price Prediction) has accelerated despite its $1 trillion scale.
LLY's Retatrutide Nears 2027 Filing With Two More Phase III Wins
Eli Lilly's retatrutide meets the primary endpoint in the phase III TRIUMPH-2 & TRIUMPH-3 studies, supporting planned regulatory submissions for obesity in 2027.
As Lilly and Novo Clash in Court, Wall Street Is Eyeing This Bigger Prize
The legal battle between Novo Nordisk and Eli Lilly is escalating, but analysts are more focused on developments in the lab.
Novo Nordisk Seeks Injunction Against Eli Lilly in Dispute Over Weight-Loss Ads
Friday's preliminary injunction request escalates legal proceedings initiated earlier this week.
Novo Nordisk seeks preliminary injunction against Lilly weight-loss ads
Novo Nordisk said on Friday it is seeking a preliminary U.S. court injunction to immediately block obesity and diabetes drug advertisements by Eli Lilly , in a further escalation of the rivalry between the two groups.
Eli Lilly Will File For Retatrutide Approval—As Study Shows Average Weight Loss Of 56 Pounds
Analysts have suggested retatrutide could become a blockbuster weight loss drug if approved. In January, TD Cowen analysts estimated retatrutide could generate $3.8 billion in sales in 2030, while GlobalData forecasts sales of $15.6 billion by 2031.
Eli Lilly Preparing Retatrutide Applications After Positive Weight-Loss Data
Eli Lilly is preparing application materials for its next-generation weight-loss drug, retatrutide, following data from two Phase 3 trials showing the treatment delivered substantial results.
Lilly announces more next-gen obesity drug data, plans Q1 2027 FDA application
Eli Lilly on Thursday said two more Phase 3 trials of its experimental obesity drug retatrutide showed positive results and it plans to submit an application to the U.S. Food and Drug Administration in the first quarter of next year.
Novo Nordisk sues Eli Lilly over weight-loss drug advertising claims
Novo Nordisk has filed a lawsuit against Eli Lilly (LLY) in a US federal court, accusing its rival of running false and misleading advertising campaigns for its blockbuster diabetes and weight-loss drugs. The lawsuit, filed Tuesday in the US District Court for the District of New Jersey, alleges that Eli Lilly and Lilly USA violated federal and state false advertising and unfair competition laws, including the Lanham Act.
